Premium
COX‐2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors
Author(s) -
van der Linden Michiel W.,
Gaugris Sabine,
Kuipers Ernst J.,
van HerkSukel Myrthe P. P.,
van den Bemt Bart J. F.,
Sen Shuvayu S.,
Herings Ron M. C.
Publication year - 2009
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1782
Subject(s) - medicine , hazard ratio , proton pump inhibitor , pharmacoepidemiology , confidence interval , proportional hazards model , cohort , poisson regression , pharmacology , population , medical prescription , environmental health
Purpose To compare hospitalization rates for serious upper and lower gastrointestinal (GI) events between chronic and acute users of a traditional non‐steroidal anti‐inflammatory drugs (tNSAID) + proton pump inhibitor (PPI) and users of a COX‐2 selective inhibitor (Coxib). Methods The PHARMO Record Linkage System, including linked drug‐dispensing and hospital records of approximately 3 million individuals in the Netherlands was used. We selected new Coxib or tNSAID users (01/01/2000–31/12/2004) with ≥1 year history before the first NSAID dispensing and ≥1 year follow‐up ending at the first hospitalization for GI event (the outcome), last dispensing, or end of the study period. Chronic users were patients who used any NSAIDs for ≥60 days during the first year ( n = 58 770); others were acute users ( n = 538 420). Multivariate analysis was performed by Poisson regression adjusted for gender, age, and duration of follow‐up, tNSAID and Coxib dose, NSAID/PPI adherence, use of other gastroprotective agents, anticoagulants, acetaminophen, corticosteroids, and cardiovascular disease. Results The cohort included 23 999 new tNSAIDs + PPI users and 25 977 new Coxib users, with main characteristics: mean ± SD age 58.1 ± 15.5 vs . 56.7 ± 17.5; female 55.3% vs . 62.2%; duration of treatment (days): 137 ± 217 vs . 138 ± 179, respectively. Among acute users, adjusted hazard ratios (95% Confidence Interval) were 0.21 (0.14–0.32) for upper and 0.26 (0.16–0.42) for lower GI events, for Coxib versus tNSAIDs + PPI users. Among chronic users, these were 0.35 (0.22–0.55) for upper GI and 0.43 (0.25–0.75) for lower GI events. Conclusions Coxib users had significantly lower rates of GI events. Further research should elucidate the possible impact of selection bias. Copyright © 2009 John Wiley & Sons, Ltd.